{"protocolSection": {"identificationModule": {"nctId": "NCT01296412", "orgStudyIdInfo": {"id": "0431-403"}, "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)", "officialTitle": "A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy"}, "statusModule": {"statusVerifiedDate": "2017-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-03-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2012-02-29", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-02-29", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-02-14", "studyFirstSubmitQcDate": "2011-02-14", "studyFirstPostDateStruct": {"date": "2011-02-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-02-05", "resultsFirstSubmitQcDate": "2013-02-05", "resultsFirstPostDateStruct": {"date": "2013-03-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-05-09", "lastUpdatePostDateStruct": {"date": "2017-06-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with Type 2 Diabetes that is not adequately controlled with metformin alone. The primary hypothesis postulated that the mean change from baseline in hemoglobin A1c (A1C) in participants treated with a sitagliptin-based treatment is non-inferior to that of participants treated with a liraglutide-based\n\ntreatment."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 653, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin +/- glimepiride", "type": "EXPERIMENTAL", "description": "Sitagliptin 100 mg tablet orally once daily for 26 weeks. Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have received glimepiride orally for glycemic control.", "interventionNames": ["Drug: sitagliptin", "Drug: glimepiride", "Drug: metformin"]}, {"label": "Liraglutide", "type": "ACTIVE_COMPARATOR", "description": "Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.", "interventionNames": ["Drug: liraglutide", "Drug: metformin"]}], "interventions": [{"type": "DRUG", "name": "sitagliptin", "description": "100 mg tablet, orally, once daily.", "armGroupLabels": ["Sitagliptin +/- glimepiride"], "otherNames": ["MK-0431, Januvia\u00ae, Tesavel\u00ae, Xelevia\u00ae, Ristaben\u00ae"]}, {"type": "DRUG", "name": "liraglutide", "description": "0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.", "armGroupLabels": ["Liraglutide"], "otherNames": ["Victoza\u00ae"]}, {"type": "DRUG", "name": "glimepiride", "description": "starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.", "armGroupLabels": ["Sitagliptin +/- glimepiride"], "otherNames": ["Amaryl\u00ae"]}, {"type": "DRUG", "name": "metformin", "description": "metformin tablets at a dose of \u22651500 mg per day", "armGroupLabels": ["Liraglutide", "Sitagliptin +/- glimepiride"], "otherNames": ["Fortamet\u00ae, Glucophage\u00ae, Glucophage\u00ae XR, Glumetza\u00ae, Riomet\u00ae, Metgluco\u00ae, Glycoran\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1c (A1C)", "description": "A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent.", "timeFrame": "Baseline and Week 26"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose (FPG)", "description": "Change from baseline at Week 26 is defined as Week 26 minus Week 0.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants Reaching A1C Goal of <7.0%", "timeFrame": "Week 26"}, {"measure": "Percentage of Participants Reaching A1C Goal of <6.5%", "timeFrame": "Week 26"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria\n\n* Type 2 diabetes mellitus.\n* On stable dose of metformin monotherapy at a dose of at least 1500 mg per day for at least 12 weeks and a hemoglobin A1C \u22657.0% and \u226411.0%.\n* Capable of using a liraglutide pen device.\n\nExclusion criteria\n\n* History of Type 1 Diabetes mellitus.\n* Use of any oral antihyperglycemic agent (AHA) besides metformin, within the prior 12 weeks of screening.\n* Cardiovascular disorders within the past 3 months including acute coronary syndrome or new or worsening symptoms of coronary heart disease, coronary artery intervention, stroke, or transient ischemic neurological disorder.\n* Impaired liver function.\n* Impaired kidney function.\n* History of malignancy or clinically important hematological disorder that requires disease-specific treatment (chemotherapy, radiation therapy, surgery) or, in the opinion of the investigator, is likely to recur during the duration of the study.\n* History of leukemia, lymphoma, aplastic anemia, myeloproliferative or myelodysplastic diseases, thrombocytopenia, or malignant melanoma, regardless of the time since treatment.\n* Pregnancy or breastfeeding, or intention to become pregnant or donate eggs within the projected duration of the study.\n* Participation in another study with an investigational drug or device within 12 weeks prior to screening.\n* History of hypersensitivity or any contraindication to sitagliptin, liraglutide, glimepiride, or metformin based upon the labels of the country of the investigational site.\n* Participation in a weight loss program and not yet in maintenance phase, or starting of a weight loss medication (such as orlistat or phentermine) within the prior 8 weeks.\n* Surgery within the prior 4 weeks or major surgery planned during the study.\n* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).\n* User of recreational or illicit drugs or recent history (within the last year) of drug abuse or increased alcohol consumption.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "79 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "referencesModule": {"references": [{"pmid": "23604551", "type": "DERIVED", "citation": "Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, Davies MJ, Engel SS. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia. 2013 Jul;56(7):1503-11. doi: 10.1007/s00125-013-2905-1. Epub 2013 Apr 19."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf\n\nhttp://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Sitagliptin +/- Glimepiride", "description": "Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have received glimepiride for glycemic control."}, {"id": "FG001", "title": "Liraglutide", "description": "Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "326"}, {"groupId": "FG001", "numSubjects": "327"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "275"}, {"groupId": "FG001", "numSubjects": "257"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}, {"groupId": "FG001", "numSubjects": "70"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "29"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Non-compliance with study drug", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Other reason not specified", "reasons": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "13"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin +/- Glimepiride", "description": "Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have received glimepiride for glycemic control."}, {"id": "BG001", "title": "Liraglutide", "description": "Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "326"}, {"groupId": "BG001", "value": "327"}, {"groupId": "BG002", "value": "653"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.9", "spread": "10.0"}, {"groupId": "BG001", "value": "57.6", "spread": "10.8"}, {"groupId": "BG002", "value": "57.3", "spread": "10.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "148"}, {"groupId": "BG001", "value": "147"}, {"groupId": "BG002", "value": "295"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "178"}, {"groupId": "BG001", "value": "180"}, {"groupId": "BG002", "value": "358"}]}]}]}, {"title": "Hemoglobin A1c (A1C)", "description": "A1C baseline values are presented for participants with data: Sitagliptin + metformin, n=325; liraglutide + metformin, n= 325; total population, n=650", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.2", "spread": "1.1"}, {"groupId": "BG001", "value": "8.1", "spread": "0.9"}, {"groupId": "BG002", "value": "8.2", "spread": "1.0"}]}]}]}, {"title": "Fasting Plasma Glucose", "description": "FPG baseline values are presented for participants with data: Sitagliptin + metformin, n=325; liraglutide + metformin, n= 325; total population, n=650", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "174.1", "spread": "43.7"}, {"groupId": "BG001", "value": "172.9", "spread": "40.8"}, {"groupId": "BG002", "value": "173.5", "spread": "42.3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1c (A1C)", "description": "A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent.", "populationDescription": "Per-protocol population defined as participants who had a measurement at baseline and a measurement after at least 24 weeks (i.e., 168 days) of treatment, and did not have any major protocol violations.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Sitagliptin +/- Glimepiride", "description": "Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have received glimepiride for glycemic control."}, {"id": "OG001", "title": "Liraglutide", "description": "Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "253"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.32", "spread": "1.06", "lowerLimit": "-1.42", "upperLimit": "-1.23"}, {"groupId": "OG001", "value": "-1.42", "spread": "1.04", "lowerLimit": "-1.51", "upperLimit": "-1.32"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The sitagliptin-based treatment paradigm was to be declared non-inferior to the liraglutide-based treatment paradigm in lowering A1C at Week 26 if the upper bound of 95% confidence intervals of between group difference was less than the non-inferiority margin of 0.4%.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included a term for treatment paradigm and a covariate for baseline value.", "paramType": "Difference in least squares mean", "paramValue": "0.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.05", "ciUpperLimit": "0.23"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG)", "description": "Change from baseline at Week 26 is defined as Week 26 minus Week 0.", "populationDescription": "Per-protocol population defined as participants who had a measurement at baseline and a measurement after at least 24 weeks (i.e., 168 days) of treatment, and did not have any major protocol violations.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Sitagliptin +/- Glimepiride", "description": "Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have received glimepiride for glycemic control."}, {"id": "OG001", "title": "Liraglutide", "description": "Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "252"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-33.7", "spread": "46.2", "lowerLimit": "-37.5", "upperLimit": "-29.9"}, {"groupId": "OG001", "value": "-39.6", "spread": "40.3", "lowerLimit": "-43.6", "upperLimit": "-35.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included a term for treatment paradigm and a covariate for baseline value.", "paramType": "Difference in least squares mean", "paramValue": "5.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.5", "ciUpperLimit": "11.4"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Reaching A1C Goal of <7.0%", "populationDescription": "Per-protocol population defined as participants who had a measurement at baseline and a measurement after at least 24 weeks (i.e., 168 days) of treatment, and did not have any major protocol violations.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Sitagliptin +/- Glimepiride", "description": "Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have received glimepiride for glycemic control."}, {"id": "OG001", "title": "Liraglutide", "description": "Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "253"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "62.8"}, {"groupId": "OG001", "value": "72.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Miettinen & Nurminen", "paramType": "Difference in percent", "paramValue": "-9.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.4", "ciUpperLimit": "-1.5"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Reaching A1C Goal of <6.5%", "populationDescription": "Per-protocol population defined as participants who had a measurement at baseline and a measurement after at least 24 weeks (i.e., 168 days) of treatment, and did not have any major protocol violations.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Sitagliptin +/- Glimepiride", "description": "Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have received glimepiride for glycemic control."}, {"id": "OG001", "title": "Liraglutide", "description": "Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "253"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33.8"}, {"groupId": "OG001", "value": "38.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Miettinen & Nurminen", "paramType": "Difference in percent", "paramValue": "-4.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.7", "ciUpperLimit": "3.7"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "Safety analyses were performed on the all participants as treated population (defined as participants who received at least 1 dose of study therapy). Participants were included in the reporting group corresponding to the actual study treatment received. Three participants randomized to therapy did not receive any study therapy.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin +/- Glimepiride", "description": "Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have received glimepiride for glycemic control.", "seriousNumAffected": 17, "seriousNumAtRisk": 326, "otherNumAffected": 58, "otherNumAtRisk": 326}, {"id": "EG001", "title": "Liraglutide", "description": "Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \\>=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.", "seriousNumAffected": 12, "seriousNumAtRisk": 324, "otherNumAffected": 97, "otherNumAtRisk": 324}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Accidental death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Cholecystitis infective", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Craniocerebral injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Sternal fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Subcutaneous hematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Prostatic specific antigen increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Muscle haemorrhage", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}]}, {"term": "Spinal column stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}]}, {"term": "Malignant melanoma stage I", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}]}, {"term": "Squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 324}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}]}, {"term": "Ureteric stenosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Urinary tract obstruction", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Bronchitis chronic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}]}, {"term": "Emphysema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}]}, {"term": "Dermatitis allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 324}]}, {"term": "Blue toe syndrome", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}, {"term": "Peripheral ischaemia", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 324}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 7, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 42, "numAffected": 35, "numAtRisk": 324}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 10, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 73, "numAffected": 63, "numAtRisk": 324}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 6, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 25, "numAffected": 21, "numAtRisk": 324}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 21, "numAffected": 21, "numAtRisk": 324}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (14.1)", "stats": [{"groupId": "EG000", "numEvents": 89, "numAffected": 41, "numAtRisk": 326}, {"groupId": "EG001", "numEvents": 31, "numAffected": 15, "numAtRisk": 324}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Canada", "Colombia", "Czech Republic", "Denmark", "Finland", "France", "Germany", "Hong Kong", "Hungary", "Israel", "Italy", "Lithuania", "New Zealand", "Poland", "Puerto Rico", "Slovakia", "Slovenia", "Spain", "Sweden", "United Kingdom", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "D000069450", "term": "Liraglutide"}, {"id": "C000057619", "term": "Glimepiride"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000097789", "term": "Glucagon-Like Peptide-1 Receptor Agonists"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Game", "relevance": "HIGH"}, {"id": "M419", "name": "Liraglutide", "asFound": "Cessation", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M3401", "name": "Glucagon-Like Peptide-1 Receptor Agonists", "relevance": "LOW"}, {"id": "M9043", "name": "Glucagon", "relevance": "LOW"}, {"id": "M26997", "name": "Glucagon-Like Peptide 1", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}]}}, "hasResults": true}